RxDoctor Payments Data

Richelle Wortham, APRN

Family · Searcy, ARNPI 1235891417

Payments from drug & device makers

$1,553in general payments, 2019–2025

Across 85 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$981
  • Xeris Pharmaceuticals, Inc.$142
  • AstraZeneca$86
  • GSK$61
  • Lilly USA, LLC$51
  • Alkermes, Inc.$42
  • plus $190 from 10 others

What the payments were for

  • Food & beverage$1,553100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,553 in reported general payments places this provider in the 75th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$2,479
Medicare patients
64
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$138,482
MounjaroTirzepatide98$117,867
JardianceEmpagliflozin53$59,162
EliquisApixaban55$45,540
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$37,925
LinzessLinaclotide32$24,149
FarxigaDapagliflozin Propanediol29$23,756
EntrestoSacubitril/Valsartan22$23,730
TrulicityDulaglutide16$21,729
Breo ElliptaFluticasone/Vilanterol50$19,704
Synjardy XrEmpagliflozin/Metformin Hcl15$18,948
SymbicortBudesonide/Formoterol Fumarate72$16,060
JanuviaSitagliptin Phosphate14$14,185
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$12,190
Tresiba Flextouch U-100Insulin Degludec22$11,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$51$139,596114 claims
Novo NordiskOzempic$17$138,482126 claims
GSKTrelegy Ellipta, Breo Ellipta$61$57,629102 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$86$52,006112 claims
AbbVieLinzess$981$24,14932 claims
MerckJanuvia$15$14,18514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,103 family providers in Arkansas.

Other family in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →